Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis

Abstract

Abstract. Mortality rates in ESRD are unacceptably high. Disorders of mineral metabolism (hyperphosphatemia, hypercalcemia, and secondary hyperparathyroidism) are potentially modifiable. For determining associations among disorders of mineral metabolism, mortality, and morbidity in hemodialysis patients, data on 40,538 hemodialysis patients with at least one determination of serum phosphorus and calcium during the last 3 mo of 1997 were analyzed. Unadjusted, case mix-adjusted, and multivariable-adjusted relative risks of death were calculated for categories of serum phosphorus, calcium, calcium ϫ phosphorus product, and intact parathyroid hormone (PTH) using proportional hazards regression. Also determined was whether disorders of mineral metabolism were associated with all-cause, cardiovascular, infection-related, fracture-related, and vascular access-related hospitalization. After adjustment for case mix and laboratory variables, serum phosphorus concentrations Ͼ5.0 mg/dl were associated with an increased relative risk of death (1.07, 1.25, 1.43, 1.67, and 2.02 for serum phosphorus 5.0 to 6.0, 6.0 to 7.0, 7.0 to 8.0, 8.0 to 9.0, and Ն9.0 mg/dl). Higher adjusted serum calcium concentrations were also associated with an increased risk of death, even when examined within narrow ranges of serum phosphorus. Moderate to severe hyperparathyroidism (PTH concentrations Ն600 pg/ml) was associated with an increase in the relative risk of death, whereas more modest increases in PTH were not. When examined collectively, the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperphosphatemia. Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracturerelated hospitalization. Disorders of mineral metabolism are independently associated with mortality and morbidity associated with cardiovascular disease and fracture in hemodialysis patients.At present, Ͼ300,000 people in the United States are undergoing therapy for ESRD with the majority on in-center hemodialysis (1). Although extending the life of patients with ESRD should be considered one of the great medical accomplishments of the latter half of the 20th century, much remains to be improved. Mortality rates are in excess of 20% per year despite improved dialytic technology and the expenditure of considerable resources, Ͼ$22 billion per year as of 2001 (1).Numerous studies have attempted to identify risk factors for mortality and morbidity in this population. Most have shown important relations among demographic factors (e.g., older age, male gender, white race) and mortality (2,3). Comorbid conditions (e.g., diabetes, cardiovascular disease) and laboratory proxies of nutritional status (e.g., serum albumin, prealbumin, creatinine) have also been consistently associated with mortality and morbidity (4 -6). Unfortunately, few of these factors are mutable. Of those factors that potentially are influenced by changes in dialysis practice, the in...

Relationship between Plasma Fibroblast Growth Factor‐23 Concentration and Survival Time in Cats with Chronic Kidney Disease

“…In human patients, high levels of PTH are associated with an increased risk of death in CKD patients on hemodialysis;15 however, this result has not been consistent in all studies and a meta‐analysis did not demonstrate a consistent association between death and serum PTH concentration in CKD patients of varying stages 22. This study examined the association between PTH and survival time or CKD progression in the cat.…”

Surgical management of secondary hyperparathyroidism in chronic kidney disease—a consensus report of the European Society of Endocrine Surgeons

“…While there are no specific indications for PTX listed in the KDIGO guidelines, it is considered in severe renal HPT refractory to medical treatment as it proficiently and quickly lowers calcium, PTH and phosphorus levels and also aims to prevent cardiovascular complications and ectopic calcifications. With adequate vitamin D treatment in renal HPT, surgical indication shifted from severe symptoms and bone disease to correct metabolic parameters (e.g., iPTH >800 pg/ml; hypercalcemia; hyperphosphataemia) when medical treatment fails because evidence of increased mortality in CKD patients is associated with mortality due to cardiovascular complications and ectopic calcifications [7][8][9]. Thus, PTX rates in CKD are clearly affected by trends in the medical treatment (4A) [6,10,11].…”

Long-term outcome of chronic dialysis in children

“…CKD presents a host of metabolic, mechanical and inflammatory damage-inducing agents, such as mineral imbalance [64,65] associated with secondary hyperparathyroidism [66,67], inflammatory mediators [68,69], oxidative stress [70,71], hyperhomocysteinaemia [72,73], hypoalbuminaemia [74], dyslipidaemia [75], anaemia [76] and chronic fluid overload [77,78]. These factors, acting individually or in concert, result in endothelial dysfunction [72,73,79], arterial stiffness [80,81], and calcification [82], which contribute to cardiac remodelling with left ventricular hypertrophy (Fig.…”